title: Evaluation of apramycin activity against carbapenem-resistant and -susceptible strains of Enterobacteriaceae.
abstract: We evaluated activity of apramycin, a non-ototoxic/non-nephrotoxic aminocyclitol against 141 clinical Enterobacteriaceae isolates, 51% of which were non-susceptible to carbapenems (CRE). Among CRE, 70.8% were apramycin susceptible, which compared favorably to aminoglycosides in current clinical use. Our data suggest that apramycin deserves further investigation as a repurposed, anti-CRE therapeutic.
authors.affiliation: Department of Pathology, 330 Brookline Avenue - YA309, Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: kpsmith@bidmc.harvard.edu.
authors.forename: Kenneth P
authors.initials: KP
authors.lastname: Smith
authors.affiliation: Department of Pathology, 330 Brookline Avenue - YA309, Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: jekirby@bidmc.harvard.edu.
authors.forename: James E
authors.initials: JE
authors.lastname: Kirby
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004755:Enterobacteriaceae / Q000187:drug effects* / Q000302:isolation & purification; D004756:Enterobacteriaceae Infections / Q000382:microbiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D009328:Nebramycin / Q000031:analogs & derivatives* / Q000494:pharmacology; D018440:beta-Lactam Resistance
chemical_list: D000900:Anti-Bacterial Agents; D009328:Nebramycin; C011666:apramycin
keywords: Activity spectrum; Aminoglycoside; Apramycin; Carbapenem-resistant Enterobacteriaceae; Multidrug-resistance; Repurposing